Aptose Biosciences advances its Phase 1/2 TUSCANY trial, escalating tuspetinib dosing after a favorable safety review. Enrollment continues across U.S. sites.

Leverage these to understand future stock performance and identify high performing investment ideas. You can also filter these to get relevant data aligned with your investing style and specific ...

ASML’s competitive advantage and strong financials make it a buy. Learn why ASML stock’s reliance on top customers and AI ...

In our analysis, these 12 brokerage accounts stand out as the best choices for stock trading, due to their low fees, strong platforms and quality customer support. Many, or all, of the products ...

Electronic system and device provider Bel Fuse (NASDAQ:BELFA) reported Q4 CY2024 results , with sales up 7% year on year to ...

Alphabet is the cheapest Mag 7 stock, with a forward P/E ratio of only 18.2 for the fiscal year ending 2026. Click here to ...

The shares have sprung back to life thanks to China’s new stimulus programs—and Alibaba’s AI ventures. They stand to gain as much as 48%.